Loading…
Listed Indian arm of GSK plc, selling branded prescription medicines and vaccines in the Indian market.
Listed Indian arm of GSK plc, selling branded prescription medicines and vaccines in the Indian market.
Sells medicines and vaccines that originate in parent GSK's global range rather than from a large discovery programme of its own, so sales depend on doctors' prescriptions, on supply from the group and on drug price controls in India. GSK plc holds the controlling stake.
In one line: GSK's Indian pharma subsidiary.
Moat: narrow (brand, IP / patents). Access to GSK's global drug and vaccine portfolio with an established India prescriber base.
Headquarters: Mumbai, India · Founded: 1924 · Employees: 3,103
Size GlaxoSmithKline Pharmaceuticals (GLAXO.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $4.53B, the 222nd largest of 1,058 India companies the cockpit tracks. Shares closed at ₹2,525 on 6 Nov 2026.
Performance Over six months the shares gained 1.8%, against +3.3% for the median peer and 0.0% for the India market (cap-weighted) — 10th lowest of 20 in its peer set.
Growth Revenue grew 12.1% over the last twelve months (peer median +14.0%); the operating margin is 32.9% (peer median 15.7%).
Valuation It trades at 35.9× forward earnings against a peer median of 31.8× (6th most expensive of 17).
Price implies For today's price to make sense, revenue must grow about 25% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is +20 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Next results Next results expected around 15 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹41.6B | ₹38.2B | ₹37.5B | ₹34.5B | ₹32.5B |
| Revenue growth | — | +2% | +9% | +6% | — |
| Gross profit | ₹19.8B | ₹16.7B | ₹15.7B | ₹12.8B | ₹11.8B |
| EBITDA | ₹14.3B | ₹13.3B | ₹11.9B | ₹9.15B | ₹8.21B |
| Net income | ₹11.5B | ₹10.4B | ₹9.28B | ₹5.90B | ₹6.11B |
| Free cash flow | n/a | ₹9.64B | ₹13.9B | ₹6.44B | ₹5.03B |
| Capital expenditure | n/a | ₹553M | ₹230M | ₹312M | ₹440M |
| Total debt | ₹392M | ₹333M | ₹99.5M | ₹187M | ₹155M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| GlaxoSmithKline Pharmaceuticals GLAXO.NS | $4.53B | +2% | +12% | 33% | 35.9× | 25.2% |
| Pfizer PFIZER.NS | $1.87B | -19% | +12% | 34% | 21.5× | 11.2% |
| Sanofi India SANOFI.NS | $800M | -3% | -6% | 26% | 19.9× | 16.5% |
| Abbott India ABBOTINDIA.NS | $5.93B | -1% | +6% | 28% | 32.4× | 11.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | GLAXO.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.2% | +3.5% | 7th lowest of 20 |
| 6-month return | +1.8% | +3.3% | 10th lowest of 20 |
| Distance from 52-week high | -19.1% | -34.5% | 7th highest of 21 |
| Revenue growth (TTM) | +12.1% | +14.0% | 9th lowest of 19 |
| Operating margin | 32.9% | 15.7% | 5th highest of 19 |
| Forward P/E | 35.9× | 31.8× | 6th most expensive of 17 |
| Growth the price implies (Req g, 7 yrs) | 25.2% | 10.4% | 2nd most demanding of 16 |
| Growth delivered (Del g) | +5.5% | +9.7% | 6th lowest of 16 |
| Hurdle (Req g minus delivered) | +19.7 pp | -3.2 pp | 3rd most demanding of 16 |
| EV / EBITDA | 28.4× | 22.3× | 2nd most expensive of 9 |
| Net debt / EBITDA | -1.5× | -0.4× | 3rd least indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| GlaxoSmithKline Pharmaceuticals GLAXO.NS | India | $4.53B | +2% | +12% | 33% | 35.9× | 25.2% | +5.5% |
| Legend Biotech Corp. Sponsored ADR LEGN | United States | $4.53B | -17% | +60% | -4% | 64.5× | n/a | n/a |
| Camurus CAMX.ST | Sweden | $4.52B | +47% | 0% | 37% | 48.5× | 10.4% | +46.5% |
| Guangzhou Baiyunshan Pharmaceutical 0874.HK | Hong Kong | $4.56B | -23% | +6% | 3% | 7.3× | 0.7% | +4.0% |
| Emcure Pharmaceuticals EMCURE.NS | India | $4.47B | +33% | +21% | 16% | 33.9× | 14.9% | +12.7% |
| Sunshine Guojian Pharmaceutical (Shanghai) 688336.SS | China | $4.47B | -34% | +227% | 74% | 46.9× | 3.3% | +45.1% |
| Definium Therapeutics DFTX | United States | $4.47B | +51% | n/a | n/a | n/a | n/a | n/a |
| Ajanta Pharma AJANTPHARM.NS | India | $4.37B | +7% | +25% | 25% | 32.2× | 23.8% | +13.8% |
| HanmiPharm 128940.KS | South Korea | $4.36B | +2% | +14% | 16% | 16.8× | 5.0% | +7.5% |
| Humanwell Healthcare (Group) 600079.SS | China | $4.71B | +3% | -3% | 16% | 13.4× | -6.8% | +3.0% |
| Travere Therapeutics TVTX | United States | $4.76B | +16% | +49% | -3% | 16.9× | 16.7% | +19.9% |
| Novast Laboratories 301569.SZ | China | $4.82B | n/a | +3% | 27% | n/a | 42.6% | +3.1% |
| Tianjin Pharmaceutical Da Ren Tang 600329.SS | China | $4.11B | +4% | -13% | 20% | 31.4× | 17.8% | -5.8% |
| Shanghai Junshi Biosciences 1877.HK | Hong Kong | $4.08B | -39% | +36% | -14% | n/a | n/a | n/a |
| Erasca ERAS | United States | $5.04B | +42% | n/a | n/a | n/a | n/a | n/a |
| HUBEI JUMPCAN PHARMACEUTICAL 600566.SS | China | $4.05B | +6% | -4% | 32% | 14.9× | -11.5% | +0.3% |
| Yuhan 000100.KS | South Korea | $4.05B | -12% | +5% | 5% | 38.6× | 20.2% | +6.2% |
| SKBP 326030.KS | South Korea | $5.12B | -11% | +39% | 35% | 21.6× | 0.5% | +93.6% |
| Siegfried SFZN.SW | Switzerland | $3.98B | -10% | +4% | 16% | 17.8× | n/a | n/a |
| Liquidia LQDA | United States | $3.97B | +5% | +2,234% | 37% | 32.9× | 0.7% | +192.5% |
| Shenzhen Salubris Pharmaceuticals 002294.SZ | China | $5.18B | -39% | +14% | 11% | 41.6× | 15.5% | +9.7% |